Systematic Financial Management LP Cuts Stock Position in Omnicell, Inc. $OMCL

Systematic Financial Management LP lowered its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 10.5% during the 4th quarter, Holdings Channel reports. The firm owned 113,619 shares of the company’s stock after selling 13,288 shares during the period. Systematic Financial Management LP’s holdings in Omnicell were worth $5,147,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in Omnicell in the second quarter worth $26,000. First Horizon Corp raised its stake in shares of Omnicell by 54.6% in the fourth quarter. First Horizon Corp now owns 1,597 shares of the company’s stock valued at $72,000 after buying an additional 564 shares during the period. LSV Asset Management bought a new stake in shares of Omnicell in the third quarter valued at $97,000. Tower Research Capital LLC TRC raised its stake in shares of Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock valued at $146,000 after buying an additional 3,932 shares during the period. Finally, Cornerstone Investment Partners LLC bought a new stake in shares of Omnicell in the fourth quarter valued at $230,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Nnamdi Njoku sold 3,090 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the sale, the executive vice president directly owned 154,785 shares in the company, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the sale, the executive vice president owned 112,783 shares in the company, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 15,520 shares of company stock worth $607,610. 2.92% of the stock is currently owned by corporate insiders.

Omnicell Stock Performance

NASDAQ:OMCL opened at $44.41 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50. Omnicell, Inc. has a 52-week low of $26.84 and a 52-week high of $55.00. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of 100.93, a PEG ratio of 1.15 and a beta of 0.96. The business’s fifty day moving average is $38.04 and its 200 day moving average is $40.83.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.02 million. During the same period in the previous year, the company posted $0.26 EPS. The firm’s revenue for the quarter was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Research analysts predict that Omnicell, Inc. will post 1.31 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price on the stock in a research note on Wednesday, February 4th. Craig Hallum restated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research note on Wednesday, April 29th. KeyCorp boosted their target price on Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Finally, UBS Group set a $60.00 target price on Omnicell and gave the company a “buy” rating in a research note on Friday, March 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $59.86.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.